Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
follow-up by maximizing positive results. Extension of testing indications to contain the epidemic requires biologists to adapt their practices. A further study accurately describing clinical features would allow for a more appropriate prescription of tests.

Disclosure of interest

The authors declare that they have no competing interest.

Ethical Approval

All procedures performed in studies involving human participants were in accordance with the 1964 Helsinki declaration and its later amendments.

References

[1] Kokkinakis I, Selby K, Favrat B, Genton B, Cornuz J. Covid-19 diagnosis: clinical recommendations and performance of nasopharyngeal swab-PCR. Rev Med Suisse 2020;16:669-699–701.
[2] Ministère des Solidarités et de la Santé. COVID-19. Recommandations aux professionnels de santé en charge des prélèvements de dépistage par RT-PCR. Fiche ARS. [Internet]. Ministère des Solidarités et de la Santé: 2020 [quoted on 22th may 2020] https://solidarites-sante.gouv.fr/IMG/pdf/covid-19_rt-PCR-ambulatoire-fiche-ars.pdf.
[3] Santé publique France. COVID-19 : point épidémiologique en Auvergne-Rhône-Alpes du 9 avril 2020. [Internet]. Santé publique France: 2020 [quoted on 22th may 2020] https://www.santepubliquefrance.fr/regions/auvergne-rhone-alpes/documents/bulletin-regional/2020/covid-19-point-epidemiologique-en-auvergne-rhone-alpes-du-9-avril-2020.

Interleukin-6 and severity of COVID-19 patients in Hefei, China

A R T I C L E   I N F O

Keywords:
COVID-19
Severity
Interleukin 6

According to existing reports, the COVID-19 pandemic resulted in more than 20% of severe cases that required critical care, and the case fatality is around 2.84% [1]. In the present study, we analysed clinical and laboratory data from 75 patients with confirmed COVID-19 hospitalised in a designated hospital in Hefei, Anhui province, China, and investigated potential indicators for infection severity.

The most common laboratory abnormalities observed in this study were decreased total lymphocytes, prolonged APTT, elevated LDH, C-reactive protein (CRP), and erythrocyte sedimentation rate (ESR). Previous studies of COVID-19 patients in Wuhan suggested virus infection could induce a cytokine storm syndrome [2,3]. Here, most patients showed elevated inflammatory factors, e.g. CRP and ESR. Forty-nine patients were tested for IL-6, and 14 (28.57%) of them showed levels above the normal range, of which lymphocyte percentage, CD4^+, and CD8^+ T cell counts were significantly decreased and neutrophil percentage, CRP, and LDH levels increased significantly, compared with patients with normal IL-6 range.

Further analysis of severe/critical and non-severe (i.e., mild and moderate) groups demonstrated that the severe group had significantly increased IL-6, CRP, PCT, and LDH levels. On the contrary, the same group had significantly decreased lymphocyte percentage, CD4^+, and CD8^+ T cell counts although with higher number of total WBC and neutrophils (Fig. 1). PCT values were within normal range in both groups. This data indicated a potential correlation between increased IL-6 levels and severity of the viral infection and the resulting inflammation.

IL-6 is produced at the inflammation site and is the chief stimulator of the acute phase response [4]. A complex of IL-6 and sIL-6Rα can activate endothelial cells to secrete IL-8 and monocyte chemoattractant protein (MCP)-1, and induce expression of adhesion molecules [5]. IL-6 also elicits specific cellular and humoral immune responses, including end-stage B cell differentiation, immunoglobulin secretion, and T cell activation. Elevated IL-6 might lead to redistribution of T cells in the lung and respiratory tract in response to the viral infection observed post-mortem in COVID-19 patients [6].

Similarly to SARS-CoV, angiotensin converting enzyme II (ACE2) is also the cellular entry receptor of COVID-19 [7,8]. ACE2 is highly expressed in human lung tissues, the gastrointestinal tract, vascular endothelial cells, and arterial smooth muscle cells [9]. Therefore, all of these organs might be targets for virus attack. Our study showed that LDH levels were increased in 44% of patients and significantly increased in the patient with higher IL-6 production and liver and/or kidney dysfunction (Table 1). This data suggests strong evidence of multiple organ damage by the virus and predicts disease severity.

This study provides an assessment of the clinical and laboratory profiles of COVID-19 patients with various severity degrees in Hefei, China. Clinical manifestations of COVID-19 were non-specific. Hematological profiles including lymphocytes, LDH, CRP, and procalcitonin, especially IL-6, might be used

[4] Lippi G, Simundic A-M, Plebani M. Potential preanalytical and analytical vulnerabilities in the laboratory diagnosis of coronavirus disease 2019 (COVID-19). Clin Chem Lab Med 2020;58:1070–6.
[5] Yang Y, Yang M, Shen C, Wang F, Yuan J, Li J, et al. Evaluating the accuracy of different respiratory specimens in the laboratory diagnosis and monitoring the viral shedding of 2019-nCoV infections. medRxiv 2020;2020.02.11.20021493.
[6] Guan W, Ni Z, Hu Y, Liang W, Ou C, He J, et al. Clinical Characteristics of Coronavirus Disease 2019 in China. N Engl J Med 2020;382:1708–20. NEJMoa2002032.
Neutrophils

Mild/moderate

IL-6:

Note:

Table

Differences

Fig.

630

Blood

P

* presented

Procalcitonin

Lactate

Creatine

Serum

Total

Aspartate

Percentage

Percentage

Neutrophils

C-reactive

Erythrocyte

Troponin

CD4/CD8

CD8

CD4

Lymphocytes

Leucocytes

CRP

PCT

IL-6

LDH

Fig. 1. Differences of laboratory findings between mild/moderate and severe/critical patients. (a) Absolute counts of WBC, neutrophils, and lymphocytes; (b) Percentage of neutrophils and lymphocytes; (c) CD4+ and CD8+ T cell counts; (d)-(f) Changes of infection indicators, CRP, PCT, and IL-6 in two groups; and (g) Detection of LDH levels. Data is presented as median (IQR) and analysed by Mann–Whitney test. All statistical analyses were performed using GraphPad Prism 8.3. P values indicate differences between mild/moderate and severe/critical patients (⁎P < .05, **P < .005, ***P < .001, ****P < .0001). P < .05 was considered statistically significant.

Differences des résultats de laboratoire entre les patients légers/modérés et sévères/critiques.

Table

Laboratory findings of patients with elevated and normal IL-6 level.

Comparaison des indices de laboratoire entre le groupe normal et le groupe élevé d’interleukine 6.

| Blood routine | Median (IQR) | Elevated IL-6 (n = 14) | Normal IL-6 (n = 35) | P value |
|---------------|--------------|------------------------|----------------------|---------|
| Leucocytes (×10⁹ per L; normal range 3.5–9.5) | 6.23 (4.13–6.86) | 5.44 (3.9–6.63) | 0.45 |
| Neutrophils (×10⁹ per L; normal range 1.8–6.3) | 5.09 (3.36–5.66) | 3.43 (1.81–4.75) | 0.1055 |
| Percentage of neutrophils (%; normal range 40–75) | 78.02 (66.88–85.81) | 70.54 (58.45–78.32) | 0.0443* |
| Lymphocytes (×10⁹ per L; normal range 1.1–3.2) | 0.79 (0.53–1.11) | 1.05 (0.67–1.79) | 0.1055 |
| Percentage of lymphocytes (%; normal range 20–50) | 14.61 (8.52–24.03) | 21.58 (14.15–32.59) | 0.0624* |
| CD4 (cell/μL; normal range 410–1590) | 322 (138.5–420.5) | 511.6 (242.8–816.5) | 0.0367* |
| CD8 (cell/μL; normal range 238–1250) | 1534 (119.2–228.4) | 305.4 (179.6–651.8) | 0.0021* |
| CD4/CD8 (normal range 0.9–3.6) | 1.57 (0.930–2.46) | 1.41 (0.53–1.78) | 0.2081 |
| Blood biochemistry | | | |
| Alanine aminotransferase (IU/L; normal range 7–40) | 27.5 (13.5–43.75) | 23 (16.00–47) | 0.9782 |
| Aspartate aminotransferase (IU/L; normal range 13–40) | 27 (21.75–39.50) | 28 (20–38) | 0.6028 |
| Total bilirubin (μmol/L; normal range 3.4–21.0) | 13.45 (9.38–16.45) | 14.3 (10.7–18.3) | 0.5217 |
| Serum creatinine (μmol/L; normal range 41–81) | 72.5 (59.75–81.75) | 67 (60–79) | 0.5727 |
| Creatine kinase (IU/L; normal range 22.0–209.0) | 86.2 (66.95–240.3) | 92.85 (56.45–144.3) | 0.6619 |
| Lactate dehydrogenase (IU/L; normal range 120–250) | 318 (252.5–408.8) | 230 (177.8–319.3) | 0.027* |
| Troponin I (μg/L; normal range 0–0.3) | 0.26 (0.09–0.77) | 0.08 (0.07–0.29) | 0.0955 |
| Infection-related biomarkers | | | |
| C-reactive protein (mg/L; normal range 0–8.0) | 76.45 (21.53–110.5) | 9.0 (3.26–23.10) | 0.0003* |
| Erythrocyte sedimentation rate (mm/h; normal range 0–15) | 69 (19.50–115.4) | 29.10 (13.40–62.25) | 0.127 |
| Procalcitonin (ng/mL; normal range 0–0.5) | 0.23 (0.17–0.29) | 0.15 (0.11–0.18) | 0.0017* |

Note: data is presented as median (IQR) or n (%). Statistical analysis: Mann–Whitney test. P values indicate differences between patients with elevated and normal IL-6 level. IL-6: interleukin-6.

* P < .05 was considered statistically significant.
as indicators for disease severity and guidance for COVID-19 treatment.

**Ethical statement and approval**

The study was approved by the Ethics Committee of the First Affiliated Hospital of USTC. All procedures performed in studies involving human participants complied with the 1964 Helsinki declaration and its later amendments.

**Funding**

This work was funded by the Special Project for Emergency Scientific and Technological Research on New Coronavirus Infection (XM, No. YD9110002001; YG, No. YD9110002009) supported by “the Fundamental Research Funds for the Central Universities”, and the Key Research and Development Plan Project of Anhui Science and Technology Department (YG, No. 201904b11020044).

**Contribution**

ZZ, MY, JjX, Y, and CD collected the clinical and laboratory data and drafted the article. YG and XM revised the final article and take responsibility for data integrity.

**Disclosure of interest**

The authors declare that they have no competing interest.

**References**

[1] Wang W, Tang J, Wei F. Updated understanding of the outbreak of 2019 novel coronavirus (2019-nCoV) in Wuhan, China. J Med Virol 2020;92:441–7.

[2] Chen N, Zhou M, Dong X, et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet 2020;395:507–13.

[3] Wang D, Hu B, Hu C, et al. Clinical characteristics of 138 hospitalised patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China. JAMA 2020, http://dx.doi.org/10.1001/jama.2020.1585.

[4] Gauldie J, Richards C, Harnish D, Landsorp P, Baumann H. Interferon beta 2B-cell stimulatory factor type 2 shares identity with monocyte-derived hepatocyte-stimulating factor and regulates the major acute phase protein response in liver cells. Proc Natl Acad Sci U S A 1987;84:7251–5.

[5] Romano M, Sironi M, Toniatti C, et al. Role of IL-6 and its soluble receptor in induction of chemokines and leukocyte recruitment. Immunity 1997;6:315–25.

[6] Yao XH, Li TY, He ZC, et al. A pathological report of three COVID-19 cases by minimally invasive autopsies. Zhonghua Bing Li Xue Za Zhi 2020;49:E9.

[7] Zhou P, Yang X, Wang X, et al. A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature 2020, http://dx.doi.org/10.1038/s41586-020-2012-7.

[8] Wan Y, Shang J, Graham R, Baric RS, Li F. Receptor recognition by novel coronavirus from Wuhan: an analysis based on decade-long structural studies of SARS. J Virol 2020, http://dx.doi.org/10.1128/JVI.00127-20.

[9] Hamming I, Timens W, Bulthuis ML, Lely AT, Navis G, van Goor H. Tissue distribution of ACE2 protein, the functional receptor for SARS coronavirus. A first step in understanding SARS pathogenesis. J Pathol 2004;203:631–7.

Z. Zhao, J. Xie, M. Yin, Y. Yang, C. Ding, Y. Gao, X. Ma

* Department of Infectious Diseases, The First Affiliated Hospital, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, Anhui, 230001, China

‡ Department of Dermatology, The First Affiliated Hospital, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, Anhui, 230001, China

§ Department of ICU, Hefei Infectious Diseases Hospital, Hefei, Anhui, 230000, China

 institute.

**Corresponding author at: Department of Infectious Diseases, The First Affiliated Hospital, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, Anhui, 230001, China.

** Co-corresponding author at: Department of Laboratory Medicine, The First Affiliated Hospital, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, Anhui, 230001, China.

E-mail addresses: ygao387@ustc.edu.cn (Y. Gao), xiaolingga@126.com (X. Ma)

These authors contributed equally to the present study.

Received 22 May 2020
Received in revised form 8 June 2020
Accepted 24 June 2020

https://doi.org/10.1016/j.medmal.2020.06.005
0399-077X/ © 2020 Elsevier Masson SAS. All rights reserved.